INHIBITOR THERAPTICS INC - INTI STOCK NEWS

Welcome to our dedicated page for INHIBITOR THERAPTICS news (Ticker: INTI), a resource for investors and traders seeking the latest updates and insights on INHIBITOR THERAPTICS stock.

Inhibitor Therapeutics, Inc. (INTI) is a Tampa-based company focusing on groundbreaking cancer treatments through angiogenesis inhibitors. Recently, they secured a licensing agreement with Johns Hopkins University for their patent on New Angiogenesis Inhibitors, targeting Prostate Cancer, Basal Cell Carcinoma, and Lung Cancer. Their innovative approach blocks blood vessel growth to combat tumor development, offering hope for patients with unmet medical needs.

08/22/2024 09:00 AM

News

Inhibitor Therapeutics, Inc. Provides Update on its Clinical Development Plan

Rhea-AI Summary

Inhibitor Therapeutics, Inc. (OTCQB: INTI) has provided an update on its clinical development plan for an itraconazole formulation to treat Basal Cell Carcinomas in Gorlin Syndrome patients. The company has submitted a Pre-Investigational New Drug application (PIND) to the FDA and received preliminary comments. INTI has engaged Avior Bio to develop a new proprietary formulation of itraconazole, which will be bridged to the formulation used in their completed clinical study via a pharmacokinetic study.

The completed clinical study showed promising results, with 399 out of 477 targeted tumors showing reduction, 275 tumors (57.7%) achieving a clinically meaningful reduction of 30% or greater, and 130 tumors (27.3%) resolving completely. Inhibitor aims to submit an Investigational New Drug Application (IND) to the FDA by the end of Q1 2025.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

19.05%

Introducing Inhibitor Therapeutics, Inc. New Scientific Advisory Board

Rhea-AI Summary

Inhibitor Therapeutics, Inc. (INTI) aims to treat Basal Cell Carcinoma Nevus Syndrome (BCCNS) with Itraconazole. The Scientific Advisory Board (SAB) is reviewing the Phase 2b trial results to assess clinical usefulness prior to submitting the New Drug Application (NDA) to FDA.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Inhibitor Therapeutics, Inc. Exclusive License with Johns Hopkins University

Rhea-AI Summary

Inhibitor Therapeutics, Inc. (INTI) has entered into an exclusive licensing agreement with Johns Hopkins University for their U.S Patent 8,980,930, focusing on the use of Itraconazole as an angiogenesis inhibitor in prostate cancer, basal cell carcinoma, and lung cancer. The License is expected to yield a modest annual royalty rate with milestone payments typical to such a license.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

44.74%

FAQ

What is the current stock price of INHIBITOR THERAPTICS (INTI)?

The current stock price of INHIBITOR THERAPTICS (INTI) is $0.067 as of January 10, 2025.

What is the market cap of INHIBITOR THERAPTICS (INTI)?

The market cap of INHIBITOR THERAPTICS (INTI) is approximately 10.3M.

What is Inhibitor Therapeutics, Inc. known for?

Inhibitor Therapeutics, Inc. is known for developing cutting-edge cancer treatments focusing on angiogenesis inhibitors.

What recent achievement did Inhibitor Therapeutics, Inc. accomplish?

Inhibitor Therapeutics, Inc. recently secured a licensing agreement with Johns Hopkins University for their New Angiogenesis Inhibitors patent.

What is the focus of Inhibitor Therapeutics, Inc.'s licensed patent?

The licensed patent of Inhibitor Therapeutics, Inc. targets Prostate Cancer, Basal Cell Carcinoma, and Lung Cancer by blocking blood vessel growth to combat tumor development.

How does Inhibitor Therapeutics, Inc.'s approach differ from traditional cancer treatments?

Inhibitor Therapeutics, Inc.'s approach focuses on inhibiting angiogenesis, the growth of blood vessels that support tumor growth, rather than directly targeting tumor cells.

What impact does Inhibitor Therapeutics, Inc.'s licensing agreement have on the medical field?

The licensing agreement of Inhibitor Therapeutics, Inc. with Johns Hopkins University opens new possibilities for treating cancers with unmet medical needs.

Where is Inhibitor Therapeutics, Inc. based?

Inhibitor Therapeutics, Inc. is based in Tampa, Florida, United States.

How can I learn more about Inhibitor Therapeutics, Inc.?

For more information about Inhibitor Therapeutics, Inc. and their mission, visit their website at www.inhibitortx.com.

What is the focus of Inhibitor Therapeutics, Inc.'s Phase 2b SCORING Trial?

Inhibitor Therapeutics, Inc.'s Phase 2b SCORING Trial focuses on Lesion Response, showing promising results in reducing tumor size and resolving lesions.

What type of patents does Inhibitor Therapeutics, Inc. hold?

Inhibitor Therapeutics, Inc. holds patents for New Angiogenesis Inhibitors, targeting specific types of cancer with innovative treatment methods.

How does Inhibitor Therapeutics, Inc.'s approach to cancer therapy contribute to patient care?

Inhibitor Therapeutics, Inc.'s approach offers hope for patients with Prostate Cancer, Basal Cell Carcinoma, and Lung Cancer by addressing unmet medical needs through angiogenesis inhibitors.